Arca
Skip to content
Tools
Tools

Mucopolysaccharidosis II

Drug research and approvals for mucopolysaccharidosis II: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 10 studies of mucopolysaccharidosis II are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 10
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting now

Newest posted first, of 10 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 2

Phase 2 4

Phase 1 or earlier 2

How its trials ended

70 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 15 whose ending is known, 47% met their primary endpoint, 0% missed it and 53% stopped early.

  • Completed, result not reported2840%
  • Ongoing2536%
  • Met its primary endpoint710%
  • Stopped: other or unclear34%
  • Stopped: lack of efficacy23%
  • Stopped: enrollment or feasibility23%
  • Status unknown23%
  • Stopped: sponsor or business decision11%

FDA orphan designations

Approved first, then open designations, newest first
Jul 24, 2006ElapraseIndicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in…Takeda Pharmaceuticals U.S.A., Inc.Approved
Sep 1, 2016Recombinant adeno-associated virus vector serotype 9…Treatment of mucopolysaccharidosis II, also called Hunter syndrome A.University of North Carolina at Chapel HillDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jan 8, 2007ElapraseIdursulfaseTakeda Pharmaceuticals International AG Ireland BranchEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.